Related Articles
Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate
Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: Determination of a suitable biopsy site for diagnosis
Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Breast-conservation treatment for bilateral breast cancer in five Japanese women
CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients